GlaxoSmithKline study shows long-term benefits of Benlysta for lupus

GlaxoSmithKline has announced the findings of a new study that demonstrates the prolonged benefits offered by its lupus therapy Benlysta.

Data from the ten-year continuation study has indicated that Benlysta, when added to standard-of-care therapy, can deliver prolonged control of disease activity in patients with active systemic lupus erythematosus (SLE).

Moreover, the percentage of those responding to treatment with Benlysta increased over time, with an overall response of 65.1 percent at year ten. Patients were also able to decrease their corticosteroid dose over time – an important goal, as corticosteroid use is associated with significant side effects.

Additionally, the study showed that the rate of adverse events remained relatively stable over time, with its performance seen as consistent with the known profile for the drug.

David Roth, medicines development leader for immuno-inflammation research and development at GlaxoSmithKline, said the drug "has consistently proven its effectiveness, with four successful pivotal trials in SLE, and data now shows that the disease control is sustained, helping to stabilise day-to-day symptoms and improve outcomes for patients in the longer term".

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.